Cytek Biosciences (CTKB) Revenue & Revenue Breakdown
Cytek Biosciences Revenue Highlights
Latest Revenue (Y)
$111.11M
Latest Revenue (Q)
$51.50M
Main Segment (Y)
Product
Main Geography (Y)
UNITED STATES
Cytek Biosciences Revenue by Period
Cytek Biosciences Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-12-31 | $111.11M | -42.44% |
| 2023-12-31 | $193.01M | 17.67% |
| 2022-12-31 | $164.04M | 28.20% |
| 2021-12-31 | $127.95M | 37.82% |
| 2020-12-31 | $92.84M | 60.39% |
| 2019-12-31 | $57.88M | - |
Cytek Biosciences generated $111.11M in revenue during NA 2024, up -42.44% compared to the previous quarter, and up 191.95% compared to the same period a year ago.
Cytek Biosciences Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-09-30 | $51.50M | 10.47% |
| 2024-06-30 | $46.62M | 3.92% |
| 2024-03-31 | $44.86M | -22.96% |
| 2023-12-31 | $58.23M | 21.32% |
| 2023-09-30 | $48.00M | -3.41% |
| 2023-06-30 | $49.69M | 33.99% |
| 2023-03-31 | $37.09M | -23.27% |
| 2022-12-31 | $48.34M | 19.42% |
| 2022-09-30 | $40.48M | 0.79% |
| 2022-06-30 | $40.16M | 14.53% |
| 2022-03-31 | $35.06M | -9.85% |
| 2021-12-31 | $38.89M | 13.14% |
| 2021-09-30 | $34.38M | 13.05% |
| 2021-06-30 | $30.41M | 25.28% |
| 2021-03-31 | $24.27M | -20.73% |
| 2020-12-31 | $30.62M | 22.01% |
| 2020-09-30 | $25.10M | 31.15% |
| 2020-06-30 | $19.14M | 6.38% |
| 2020-03-31 | $17.99M | - |
Cytek Biosciences generated $51.50M in revenue during Q3 2024, up 10.47% compared to the previous quarter, and up 103.64% compared to the same period a year ago.
Cytek Biosciences Revenue Breakdown
Cytek Biosciences Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|
| Service | $47.19M | $36.49M | $15.44M | $8.43M |
| Product | $153.26M | $156.72M | $148.60M | $119.52M |
Cytek Biosciences's latest annual revenue breakdown by segment (product or service), as of Dec 24: Product (76.46%), and Service (23.54%).
Quarterly Revenue by Product
| Product/Service | Dec 24 | Sep 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product | $79.60M | $39.54M | $34.12M | $46.65M | $38.44M | $40.45M | $31.17M | $43.64M | $36.39M | $37.09M | $31.48M | $35.95M | $32.19M | $28.68M |
| Service | - | $39.00M | $36.87M | - | $37.00M | $9.24M | $5.92M | $4.70M | $4.09M | $3.07M | $3.58M | $2.94M | $2.19M | $1.73M |
Cytek Biosciences's latest quarterly revenue breakdown by segment (product or service), as of Dec 24: Product (100.00%).
Cytek Biosciences Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|
| Other | $9.73M | $6.15M | $2.96M | $2.18M |
| EMEA | $62.34M | $53.18M | $43.96M | $36.97M |
| Asia Pacific | $35.77M | $31.60M | $22.52M | $16.08M |
| UNITED STATES | $92.61M | $102.08M | $94.59M | $72.72M |
Cytek Biosciences's latest annual revenue breakdown by geography, as of Dec 24: UNITED STATES (46.20%), EMEA (31.10%), Asia Pacific (17.84%), and Other (4.86%).
Quarterly Revenue by Country
| Country | Dec 24 | Sep 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asia Pacific | $20.48M | $8.94M | $6.35M | $11.57M | $6.76M | $7.05M | $6.22M | $4.22M | $7.15M | $6.14M | $5.01M | $6.63M | $2.80M | $3.39M |
| EMEA | $29.98M | $17.23M | $15.13M | $21.14M | $12.92M | $9.08M | $10.03M | $16.14M | $10.30M | $8.84M | $8.68M | $13.48M | $6.18M | - |
| Other | $6.73M | $979.00K | $2.02M | $1.51M | $1.53M | $2.12M | $996.00K | $1.29M | $212.00K | $418.00K | $1.04M | $633.00K | $1.42M | $111.00K |
| UNITED STATES | $46.90M | $24.35M | $21.36M | $24.02M | $26.79M | $31.44M | $19.84M | $26.70M | $22.81M | $24.76M | $20.32M | $18.14M | $23.98M | $17.25M |
| E M E A | - | - | - | - | - | - | - | - | - | - | - | - | - | $9.66M |
Cytek Biosciences's latest quarterly revenue breakdown by geography, as of Dec 24: UNITED STATES (45.05%), EMEA (28.81%), Asia Pacific (19.68%), and Other (6.46%).
Cytek Biosciences Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| LIVN | LivaNova | $1.25B | $318.11M |
| INGN | Inogen | $335.70M | $88.83M |
| TMCI | Treace Medical Concepts | $209.36M | $45.09M |
| KIDS | OrthoPediatrics | $204.73M | $52.80M |
| AXGN | AxoGen | $187.34M | $48.64M |
| RXST | RxSight | $139.93M | $45.41M |
| SRDX | Surmodics | $126.08M | $29.92M |
| CTKB | Cytek Biosciences | $111.11M | $51.50M |
| LUNG | Pulmonx | $83.79M | $20.39M |
| NPCE | NeuroPace | $79.91M | $21.06M |
| SGHT | Sight Sciences | $79.87M | $20.16M |
| APYX | Apyx Medical | $48.10M | $16.02M |
| SSKN | STRATA Skin Sciences | $33.56M | $8.44M |
| OFIX | Orthofix Medical | - | $198.62M |